ALLG AMLM31: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study.

Authors
Category Primary study
Registry of TrialsAustralian New Zealand Clinical Trials Register
Year 2025
This article has no abstract
Epistemonikos ID: 123776fb6fa66473b2395fb03c0b5658cb5b03f8
First added on: Sep 12, 2025